Andrea Russo, MD
Urogynecology and Reconstructive Pelvic Surgery · Danbury, CTNPI 1922311307
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,466 of the $7,589 with a category attached, or 72.0%. It is spread thinly across 40 manufacturers, the largest accounting for just 22.5%.
Across 251 payments — averaging $30.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$2K
- AbbVie$768
- Astellas Pharma US Inc$716
- Sumitomo Pharma America, Inc.$682
- Abbott$642
- Axonics, Inc.$473
- plus $3K from 34 others
What the payments were for
- Travel & lodging$1,39218%
- Food & beverage$5,46672%
- Education$73110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 25 | $1,706 |
| AbbVie(2 entities) | 33 | $768 |
| Astellas Pharma US Inc | 37 | $716 |
| Sumitomo Pharma America, Inc. | 29 | $682 |
| Abbott | 2 | $642 |
| Axonics, Inc. | 13 | $473 |
| Boston Scientific | 7 | $356 |
| Urogen Pharma, Inc. | 6 | $170 |
| 180 Medical, Inc. | 8 | $153 |
| Tolmar, Inc. | 5 | $143 |
| Urovant Sciences Inc | 10 | $143 |
| Progenics Pharmaceuticals, Inc. | 6 | $132 |
| Therapeuticsmd, Inc. | 6 | $128 |
| Endo USA, Inc. | 5 | $115 |
| Merck | 5 | $110 |
| Medtronic(2 entities) | 4 | $107 |
| Teleflex LLC | 5 | $94 |
| Amgen | 5 | $88 |
| Mission Pharmacal Company | 5 | $75 |
| Rochester Medical Corporation | 2 | $74 |
| Johnson & Johnson | 4 | $68 |
| Vertex | 3 | $63 |
| KARL Storz Endoscopy-america | 3 | $56 |
| Blue Earth Diagnostics | 1 | $53 |
| Endo Pharmaceuticals Inc. | 3 | $52 |
| Bayer | 2 | $51 |
| Accord Healthcare, Inc. | 2 | $49 |
| Immunitybio, Inc. | 2 | $44 |
| Dendreon Pharmaceuticals LLC | 1 | $33 |
| Tolmar Pharmaceuticals, Inc. | 2 | $33 |
| Histosonics, Inc. | 1 | $32 |
| Civco Medical Instruments | 1 | $28 |
| Myovant Sciences Inc. | 1 | $27 |
| Calyxo, Inc. | 1 | $25 |
| Novo Nordisk | 1 | $25 |
| Neotract Inc. | 1 | $22 |
| Caldera Medical, Inc | 1 | $16 |
| Laborie Medical Technologies Corp. | 1 | $14 |
| Metuchen Pharmaceuticals | 1 | $12 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$825
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$633
- BOTOX$136
- GENERAL - THERAPIES$119
- Axonics$112
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 670 | $518,857 |
| MyrbetriqMirabegron | 637 | $453,874 |
| Estradiol | 393 | $26,030 |
| Mirabegron ErMirabegron | 19 | $17,266 |
| Methenamine Hippurate | 180 | $11,128 |
| Trospium Chloride ErTrospium Chloride | 44 | $10,184 |
| Trospium Chloride | 147 | $8,701 |
| Cephalexin | 352 | $6,011 |
| YuvafemEstradiol | 29 | $3,141 |
| Solifenacin Succinate | 44 | $2,234 |
| Oxybutynin Chloride ErOxybutynin Chloride | 48 | $2,091 |
| Tolterodine Tartrate ErTolterodine Tartrate | 23 | $1,969 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 36 | $994 |
| NitrofurantoinNitrofurantoin Macrocrystal | 17 | $685 |
| Amitriptyline Hcl | 51 | $672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $682 | $518,857670 claims |
| Astellas Pharma US IncMyrbetriq | $716 | $453,874637 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in Danbury
- Richard KershenHartford$28K
- Dmitry VolkinWaterford$15K
- Oz HarmanliNew Haven$9K
- Elena Tunitsky BittonHartford$9K
- Elisha JacksonNew Haven$4K
- Mark PrestonWaterbury$2K
- Jaclyn MunozNorwalk$2K
- Elisabeth SappenfieldHartford$2K
- Nancy RingelNew Haven$2K
- Nicole WoodHartford$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.